# FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

> **NCT04699643** · PHASE1,PHASE2 · UNKNOWN · sponsor: **EverNov Medicines (Zhuhai Hengqin) Co., Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** EVER4010001

## Key facts

- **NCT ID:** NCT04699643
- **Lead sponsor:** EverNov Medicines (Zhuhai Hengqin) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-30
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2021-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04699643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04699643, "FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04699643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*